Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis

被引：24

作者：

Blanco, Esther ^{[1
,3
]}

Beyene, Joseph ^{[2
,4
,5
]}

Maloney, Anne Marie ^{[1
]}

Almeida, Rowena ^{[2
]}

Ethier, Marie-Chantal ^{[2
]}

Winick, Naomi ^{[6
]}

Alexander, Sarah ^{[1
,3
]}

Sung, Lillian ^{[1
,2
,3
]}

机构：

[1] Hosp Sick Children, Div Hematol Oncol, Dept Paediat, Toronto, ON M5G 1X8, Canada

[2] Hosp Sick Children, Program Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada

[3] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada

[4] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada

[5] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada

[6] UT SW Med Ctr, Dept Pediat Hematol Oncol, Dallas, TX USA

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 05期

基金：

加拿大健康研究院;

关键词：

Acute lymphoblastic leukemia; pediatrics; non-relapse mortality; treatment-related mortality; risk factors; MYELOID-LEUKEMIA; CHILDHOOD-CANCER; ONCOLOGY-GROUP; DEATH; EXPERIENCE; CHILDREN; THERAPY; TRIALS; TRENDS;

D O I：

10.3109/10428194.2011.639018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The primary objective of the study was to describe non-relapse mortality (NRM) and the proportion of first events that are deaths in children with acute lymphoblastic leukemia (ALL). Secondary objectives were to identify groups at higher risk and to determine whether proportions have changed over time. We performed a systematic review of randomized pediatric ALL studies. From 1337 articles, 59 were included, comprising a total of 49 071 patients. The induction death rate was 1.38%, remission death rate was 1.94% and total NRM was 3.60%. Deaths were responsible for 53.84% of first events during induction and 13.03% in total. Standard risk patients had significantly lower NRM during remission. The year of study was not associated with NRM. The results of the study show that the rate of NRM in children with ALL is 3.60% and those with high risk ALL have significantly higher NRM during remission, but NRM has not changed over time. Future research should focus on the exploration of patient-related risk factors for NRM.

引用

页码：878 / 885

页数：8

共 17 条

[1] Trends in incidence of childhood cancer in Australia, 1983-2006 [J].

Baade, P. D. ;

Youlden, D. R. ;

Valery, P. C. ;

Hassall, T. ;

Ward, L. ;

Green, A. C. ;

Aitken, J. F. .

BRITISH JOURNAL OF CANCER, 2010, 102 (03) :620-626

[2] RATIO ESTIMATES, THE DELTA METHOD, AND QUANTAL RESPONSE TESTS FOR INCREASED CARCINOGENICITY [J].

BIELER, GS ;

WILLIAMS, RL .

BIOMETRICS, 1993, 49 (03) :793-801

[3] Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 [J].

Conter, V ;

Arico, M ;

Valsecchi, MG ;

Basso, G ;

Biondi, A ;

Madon, E ;

Mandelli, F ;

Paolucci, G ;

Pession, A ;

Rizzari, C ;

Rondelli, R ;

Zanesco, L ;

Masera, G .

LEUKEMIA, 2000, 14 (12) :2196-2204

[4] Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI) [J].

Hargrave, DR ;

Hann, IM ;

Richards, SM ;

Hill, FG ;

Lilleyman, JS ;

Kinsey, S ;

Bailey, CC ;

Chessells, JM ;

Mitchell, C ;

Eden, OB .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (02) :293-299

[5] Evaluation of the quality of prognosis studies in systematic reviews [J].

Hayden, JA ;

Côté, P ;

Bombardier, C .

ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) :427-437

[6] Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group [J].

Lange, Beverly J. ;

Smith, Franklin O. ;

Feusner, James ;

Barnard, Dorothy R. ;

Dinndorf, Patricia ;

Feig, Stephen ;

Heerema, Nyla A. ;

Arndt, Carola ;

Arceci, Robert J. ;

Seibel, Nita ;

Weiman, Margie ;

Dusenbery, Kathryn ;

Shannon, Kevin ;

Luna-Fineman, Sandra ;

Gerbing, Robert B. ;

Alonzo, Todd A. .

BLOOD, 2008, 111 (03) :1044-1053

[7] Trends in childhood cancer incidence in the US (1992-2004) [J].

Linabery, Amy M. ;

Ross, Julie A. .

CANCER, 2008, 112 (02) :416-432

[8] Risk Factors for Treatment Related Mortality in Childhood Acute Lymphoblastic Leukaemia [J].

Lund, Bendik ;

Asberg, Ann ;

Heyman, Mats ;

Kanerva, Jukka ;

Harila-Saari, Arja ;

Hasle, Henrik ;

Soderhall, Stefan ;

Jonsson, Olafur Gisli ;

Lydersen, Stian ;

Schmiegelow, Kjeld .

PEDIATRIC BLOOD & CANCER, 2011, 56 (04) :551-559

[9] Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival:: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J].

Moericke, Anja ;

Reiter, Alfred ;

Zimmermann, Martin ;

Gadner, Helmut ;

Stanulla, Martin ;

Doerdelmann, Michael ;

Loening, Lutz ;

Beier, Rita ;

Ludwig, Wolf-Dieter ;

Ratei, Richard ;

Harbott, Jochen ;

Boos, Joachim ;

Mann, Georg ;

Niggli, Felix ;

Feldges, Andreas ;

Henze, Guenter ;

Welte, Karl ;

Beck, Joern-Dirk ;

Klingebiel, Thomas ;

Niemeyer, Charlotte ;

Zintl, Felix ;

Bode, Udo ;

Urban, Christian ;

Wehinger, Helmut ;

Niethammer, Dietrich ;

Riehm, Hansjoerg ;

Schrappe, Martin .

BLOOD, 2008, 111 (09) :4477-4489

[10] Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia [J].

Moghrabi, Albert ;

Levy, Donna E. ;

Asselin, Barbara ;

Barr, Ronald ;

Clavell, Luis ;

Hurwitz, Craig ;

Samson, Yvan ;

Schorin, Marshall ;

Dalton, Virginia K. ;

Lipshultz, Steven E. ;

Neuberg, Donna S. ;

Gelber, Richard D. ;

Cohen, Harvey J. ;

Sallan, Stephen E. ;

Silverman, Lewis B. .

BLOOD, 2007, 109 (03) :896-904

← 1 2 →